Mary T Bausch-Jurken
Overview
Explore the profile of Mary T Bausch-Jurken including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
33
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang X, Pahwa A, Bausch-Jurken M, Chitkara A, Sharma P, Malmenas M, et al.
Adv Ther
. 2025 Mar;
PMID: 40063213
Introduction: This systematic literature review and pairwise meta-analysis evaluated the comparative effectiveness of mRNA-1273 versus BNT162b2 in patients with at least one underlying medical condition at high risk for severe...
2.
Kavikondala S, Haeussler K, Wang X, Bausch-Jurken M, Nassim M, Mishra N, et al.
Infect Dis Ther
. 2024 Aug;
13(10):2207-2208.
PMID: 39180647
No abstract available.
3.
Beck E, Bausch-Jurken M, Van de Velde N, Wang X, Malmenas M
Infect Dis Ther
. 2024 Aug;
13(10):2195-2202.
PMID: 39180646
No abstract available.
4.
Kavikondala S, Haeussler K, Wang X, Spellman A, Bausch-Jurken M, Sharma P, et al.
Infect Dis Ther
. 2024 May;
13(7):1419-1438.
PMID: 38802704
Introduction: Immunocompromised (IC) patients mount poor immune responses to vaccination. Higher-dose coronavirus disease 2019 (COVID-19) vaccines may offer increased immunogenicity. Methods: A pairwise meta-analysis of 98 studies reporting comparisons of...
5.
Kavikondala S, Haeussler K, Wang X, Bausch-Jurken M, Nassim M, Mishra N, et al.
Infect Dis Ther
. 2024 Mar;
13(4):779-811.
PMID: 38498109
Introduction: The mRNA vaccines mRNA-1273 and BNT162b2 demonstrated high efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in phase 3 clinical trials, including among older adults. To inform...
6.
Wang X, Haeussler K, Spellman A, Phillips L, Ramiller A, Bausch-Jurken M, et al.
Front Immunol
. 2023 Sep;
14:1204831.
PMID: 37771594
Introduction: Despite representing only 3% of the US population, immunocompromised (IC) individuals account for nearly half of the COVID-19 breakthrough hospitalizations. IC individuals generate a lower immune response after vaccination...
7.
Bausch-Jurken M, Hintermeyer M, Woodliff J, Chen S, Rymaszewski A, Verbsky J, et al.
J Clin Immunol
. 2019 Jan;
39(1):23-25.
PMID: 30627929
No abstract available.
8.
Bausch-Jurken M, Verbsky J, Gonzaga K, Elms N, Hintermeyer M, Gauld S, et al.
J Clin Immunol
. 2017 Jun;
37(5):427-433.
PMID: 28589420
Purpose: The specific antibody response to the unconjugated 23-valent pneumococcal polysaccharide vaccine is one of the most common tests used to assess for possible humoral immunodeficiency. The results can be...